SavedAdd your journal

Journals / The Anatolian Journal of Cardiology / 2018 / Cilt: 20 - Sayı: 1

Clinical implications from the European Heart Rhythm Association consensus document on antiarrhythmic drug therapy

EMİN EVREN ÖZCAN
BÜLENT GÖRENEK
Pages
48–51
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper, we reviewed novel treatment concepts offered by the consensus document.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The recently published consensus document by the European Heart Rhythm Association presents a patient-tailored pharmacological antiarrhythmictreatment approach targeting the arrhythmia mechanism.
📊
Key Findings & Data:This document comprehensively reviews the indications, side effects, and contraindicationsof antiarrhythmic drugs.
💡
Conclusion & Impact:In this paper, we reviewed novel treatment concepts offered by the consensus document.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

The recently published consensus document by the European Heart Rhythm Association presents a patient-tailored pharmacological antiarrhythmictreatment approach targeting the arrhythmia mechanism. This document comprehensively reviews the indications, side effects, and contraindicationsof antiarrhythmic drugs. In this paper, we reviewed novel treatment concepts offered by the consensus document.

🔖

Cite This Article

ÖZCAN, E. E., GÖRENEK, B. (2018). Clinical implications from the European Heart Rhythm Association consensus document on antiarrhythmic drug therapy. The Anatolian Journal of Cardiology, Cilt: 20 - Sayı: 1, 48–51. https://ajindex.com/articles/365270

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Alboni P, Botto GL, Boriani G, Russo G, Pacchioni F, Iori M, et al. Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during ‘pill-in-the-pocket’ treatment. Heart 2010; 96: 546-9. [CrossRef] Pinski SL, Helguera ME. Antiarrhythmic drug initiation in patients with atrial fibrillation. Prog Cardiovasc Dis 1999; 42: 75-90. [CrossRef] Snider M, Carnes C, Grover J, Davis R, Kalbfleisch S. Cost-benefit and cost- savings analyses of antiarrhythmic medication monitoring. Am J Health Syst Pharm 2012; 69: 1569-73. [CrossRef] K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45(4 Suppl 3): S1-153. Aronow WS, Frishman WH, Cheng-Lai A. Cardiovascular drug therapy in the elderly. In: Aronow WS, Fleg JL, Rich MW, editors. Tresch and Aronow’s Cardiovascular Disease in the Elderly. 5th edition. CRC Press;
  2. Boca. Raton, London, New York: 2013; p. 67-103.
  3. Pritchett EL, Page RL, Carlson M, Undesser K, Fava G; Rythmol Atrial Fibrillation Trial (RAFT) Investigators. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol 2003; 92: 941-6. [CrossRef] Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES et al.; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006; 295: 165-71. [CrossRef] The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12. [CrossRef] Heijman J, Voigt N, Dobrev D. New directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol 2013; 9: 71-88.
  4. Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac "late sodium current.". Pharmacol Ther 2008; 119: 326-39. [CrossRef] Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 24: 129-47. [CrossRef] Dan GA, Martinez-Rubio A, Agewall S, Boriani G, Borggrefe M, Gaita F, et al. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from